African Americans (AA) Communities Speak: Partnering With AA in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care.
African Americans are less likely to receive quality end-of-life (EoL) care. Addressing disparities in EoL care will need efforts to support a better understanding of African American patients' EoL cultural values and preferences for EoL communication and the impact of historical and ongoing care delivery inequities in healthcare settings. Our proposed "Caring for Older African Americans" training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and an implicit bias recognition and management training to mitigate bias in goals of care communication.
Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes
Cigarette smoking is now the leading killer of people with HIV (PWH) in the US, and most cessation strategies tried to date have failed to increase long-term quit rates. An "all or none" approach to smoking cessation in PWH offers little benefit to the large majority of PWH who are unable or unwilling to quit. In this proposal we argue that a harm reduction approach (i.e. cut down, get screened for lung cancer, control your blood pressure and cholesterol) has the potential to yield significant benefits in terms of the private and public health of PWH in the US.
Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation - SToP-CAV
The investigator's propose to conduct an open-label randomized controlled trial to determine if higher intensity statin (HS) can reduce CAV in comparison to lower intensity statin (LS) after HT. All consecutive patients that meet eligibility criteria will be approached for participation. After heart transplantation, participants (n=70) will be randomized in a 1:1 manner to either HS (Atorvastatin 80 mg daily) or LS (Pravastatin 40 mg daily). Study participation will be for 2 years from the time of randomization.
Abstract: Advanced pancreatic ductal adenocarcinoma (PDAC) is usually an incurable malignancy that needs newer therapeutic targets. Interleukin-1 receptor accessory protein (IL1RAP) is an innate immune mediator that regulates activation of pro-inflammatory and mitogenic signaling pathways. Immunohistochem. on tissue microarrays demonstrated expression of IL1RAP in majority of human PDAC specimens and in murine pancreatic tumors from K-RasG122D/p53R172H/PDXCre (KPC) mice. Single cell RNA-Seq anal. of human primary pre-neoplastic lesions and adenocarcinoma specimens indicated that overexpression occurs during carcinogenesis. IL1RAP overexpression was associated with worse overall survival. IL1RAP knockdown significantly reduced cell viability, invasiveness, and clonogenic growth in pancreatic cancer cell lines. Inhibition of the downstream interleukin-1 receptor-associated kinase 4 (IRAK4) using two pharmacol. inhibitors, CA-4948 and PF06650833, resulted in reduced growth in pancreatic cancer cell lines and in xenograft models.
2022-06-01·Data in Brief
Dataset on flow diversion procedures performed with the Pipeline Embolization Device, Pipeline Flex, and Surpass Streamline for intracranial aneurysms
作者: Vivanco-Suarez, Juan ; Feigen, Chaim ; Javed, Kainaat ; Dardick, Joseph M. ; Holland, Ryan ; Mendez-Ruiz, Alan ; Ortega-Gutierrez, Santiago ; Haranhalli, Neil ; Altschul, David J.
Flow diversion is an evolving endovascular modality for treating intracranial aneurysms. Although rare, serious adverse events following flow diversion may include ischemic stroke, intracranial hemorrhage, or delayed rupture of the treated aneurysm. This dataset describes 141 flow diversion procedures performed with the Pipeline Embolization Device, Pipeline Flex, or Surpass Streamline on 126 subjects with intracranial aneurysms . The retrospective data were collected from electronic medical records at two large tertiary centers. Baseline patient data included age, sex, and medical comorbidities. The dataset also describes aneurysm characteristics including laterality, anatomic location, morphology, dome height, and neck width. In addition, digital subtraction images showing the internal carotid artery tortuosity were included for aneurysms in the anterior cerebral circulation . Procedural data include case duration, radiation exposure, number of flow diverters deployed, and complications encountered during deployment. In addition, data related to the duration of hospitalization and postoperative adverse events are included. Finally, time to follow up and rates of total aneurysm obliteration at first and second postoperative visits are included. This data is propensity score matching are included. This data is presented as a starting point for future prospective comparisons in the safety and efficacy of flow diverters as more devices become approved and commercially available.
2022-04-30·American Journal of Kidney Diseases
De novo class IV + V lupus nephritis after the BNT162B2 COVID-19 vaccine
作者: Dominguez, Mary ; Terzibachi, Michel ; Acosta, Dionisio ; Pullman, James ; Fisher, Molly
Viral infection can lead to the formation of autoantibodies due to cross reactivity of self-antigens with foreign proteins. Cases describing immune-mediated glomerular diseases following SARS-CoV-2 infection have been reported worldwide. A temporal relationship between immunization and development of autoimmune diseases such as systemic lupus erythematous (SLE) has also been described. We report a case of de novo class IV + V lupus nephritis after the BNT162b2 COVID-19 vaccine. A 45 yr-old female presented with a 3 wk history of a butterfly rash, feet swelling, arthralgias and fatigue. Eight weeks prior, she received her second dose of the BNT162b2 COVID-19 vaccine. Exam revealed blood pressure 156/93 mm Hg, malar rash and 2+ lower extremity edema. Labs showed >300mg protein and large blood on dipstick, 4-10 RBCs per high power field by urine microscopy, urine protein-creatinine ratio of 11 g/g, serum albumin 2 g/dL and serum creatinine 0.8 mg/dL. Extractable nuclear antigen panel was pos. for ANA >1:1280, double-stranded DNA antibody 400 U/mL, anti-Smith antibody 480 U/mL and RNP antibody 240 U/mL. Complement C3 and C4 were 16 mg/dL and < 5mg/dL, resp. Kidney biopsy revealed class IV + V lupus nephritis. Treatment was initiated with i.v. methylprednisolone followed by oral prednisone 1mg/kg per day and mycophenolate mofetil. Within 1 mo of induction therapy, her clin. symptoms improved but her lupus nephritis has not yet remitted. To our knowledge, this is the first reported case of de novo lupus nephritis following COVID-19 vaccination. Cases of de novo and relapsing minimal change disease, IgA nephropathy, ANCA associated vasculitis and anti-GBM disease following COVID-19 vaccination have been reported. Though we hypothesize that vaccination triggered autoimmunity, it is possible that development of SLE was unrelated since her symptoms occurred > 1 mo after vaccination. Cases proposing a pathogenic association between autoimmune disease and vaccination describe symptom onset occurring within days to several weeks post-vaccination. Studies that compare the incidence of immune-mediated glomerular diseases in individuals who receive COVID-19 vaccines and unvaccinated individuals are needed to determine if there is a causal relationship.
WASHINGTON, Utah, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Yaw Ababio Boateng, MD, Ph.D., FACP, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to Nephrology.
Yaw Ababio Boateng
Dr. Boateng pursued higher education at Kwame Nkrumah University of Science and Technology School of Medical Sciences (KNUST-SMS) in Kumasi, Ghana where he earned a Bachelor of Science degree in Human Biology. He also holds a Doctor of Philosophy degree (Ph.D.) in Clinical Pharmacology from the University of Aberdeen in the UK. After relocating to the United States, he completed his internship, internal medicine residency, and nephrology fellowship at the Montefiore Medical Center North Division/New York Medical College.
According to Dr. Boateng, nephrology is a specialty of medicine that involves the kidneys and practitioners like Dr. Boateng, have advanced training in treating kidney disease from diet and medication to renal replacement therapy. The doctor diagnoses and treats kidney failure and helps patients by prescribing medications, offering particular diet advice, and coordinating dialysis care or kidney transplantation when necessary.
Dr. Boateng explained that he provides hospital and ICU consultations for patients who present with chronic kidney disease and hypertension primarily at St. George Regional Hospital in St. George, UT. He currently serves as the Medical Director of Davita Mojave Desert Dialysis Center and Davita Hurricane Dialysis Center, as well as an Assistant Clinical Professor of Medicine at the University of Utah. The doctor notes that he has completed extensive research in the area of the use of natural methods of healing, which correlates to his sub-specialties that include general nephrology; ICU nephrology; all dialysis modalities (hemodialysis, peritoneal dialysis, and home dialysis); chronic kidney disease; electrolyte abnormalities; and hypertension.
With more than 23 years of experience as a nephrologist and 39 years of experience in the medical field, Dr. Boateng is affiliated with numerous medical facilities including the University of Utah Health; Dixie Kidney Clinic in St. George, UT; Iron Mission Kidney Clinic in Cedar City, UT; Hurricane Dialysis and Kidney Clinic in Hurricane, UT; and Mojave Desert Dialysis and Kidney Clinic in Mesquite, NV. He is also a renowned author who has published numerous articles in peer-reviewed scientific journals, including the British Journal of Pharmacology; the British Journal of Clinical Pharmacology; and the European Journal of Urology and Nephrology. He asserts that his most recent publication in October 2022 is a book called "Reverse Chronic Kidney Disease- How to Improve Kidney Function and Avoid Dialysis" and it is available in eBook form and paperback on Amazon.
As a leader in the field with multiple responsibilities, Dr. Boateng manages DaVita Hurricane Dialysis Center which has 12 dialysis stations; a team of professionals to support their patients receiving dialysis; and the associated clinic that provides care for patients with kidney conditions that include chronic kidney disease, kidney stones, and other issues. The Mojave Desert Dialysis and Kidney Clinic is also under Dr. Boateng's leadership and has ten dialysis stations; a kidney (nephrology) clinic in the building; and functions in a similar manner as DaVita Hurricane Dialysis Center.
Dr. Boateng is a Fellow of the American College of Physicians (FACP) and a member of the American Society of Nephrology. Board-certified in nephrology and internal medicine by the American Board of Internal Medicine (ABIM), he explained that ABIM is a physician-led, non-profit independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.
Aside from his medical pursuits, the doctor writes and publishes children's books and currently has released three titles with Heinemann International. Dr. Boateng would like to honor the loving memory of his father, Stephen Oti-Boateng with this recognition. He has been married to Mrs. Cecilia Boateng for 39 years and they have three children. He would also like to acknowledge the guidance of his mentor, Jinil Yoo, MD, professor of Medicine at the Albert Einstein College of Medicine in New York, and the continual blessings of Almighty God.
Contact: Katherine Green, 516-825-5634, [email protected]
SOURCE The Inner Circle
Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS Therapy™ for gait improvement in Multiple Sclerosis NEWTOWN, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the addition the Montefiore Medical Center (“Montefiore”) to its PoNS Therapeutic Experience Program (“PoNSTEP”). Montefiore joins five other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (“PoNS®”) therapy in patients with multiple sclerosis (“MS”). Montefiore’s participation in the study will be held at the Burke Rehabilitation Center and led by Dr. Christopher Langston, medical director of The Madlyn Borelli Multiple Sclerosis Center at Montefiore Nyack Hospital. “Dr. Langston is a renowned clinical researcher of current and advanced topics in MS management and patient-centered care. His interest in PoNS Therapy has led him to be one of the first PoNS prescribers and his growing experience with this therapy, along with a long-standing commitment to improving MS patients’ condition, makes him a remarkable contributor to the PoNSTEP study,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. “The MS patients we treat are often in the prime of their lives. At Montefiore, we believe it’s important to understand all MS treatments available in order to guide our patients in choosing their best path. We strive to help them navigate their illness by exposing them to innovative therapies as well as giving them the opportunity to participate in advanced clinical trials. I’ve been an early adopter of PoNS Therapy to help my patients improve their gait and I'm excited to join the study,” stated Dr. Langston. About Montefiore Medical Center As the academic medical center and University hospital for Albert Einstein College of Medicine, Montefiore Medical Center is nationally recognized for clinical excellence—breaking new ground in research, training the next generation of healthcare leaders, and delivering science-driven, patient-centered care. Montefiore is ranked among the top hospitals nationally and regionally by U.S. News & World Report. For more than 100 years Montefiore has been innovating new treatments, new procedures and new approaches to patient care, producing stellar outcomes and raising the bar for medical centers in the region and around the world. Montefiore continue to advance the practice of medicine and set the standard for excellence. The mission of Montefiore is to heal, to teach, to discover and to advance the health of the communities it serves. From its beginning in 1884, as a facility for the care of patients with tuberculosis and other chronic illnesses, to the new millennium, Montefiore has been at the forefront of patient care, research and education and steadfast commitment to its community. About The Madlyn Borelli Multiple Sclerosis Center The Madlyn Borelli Multiple Sclerosis Center at Montefiore Nyack Hospital provides comprehensive care for people with MS. Affiliated with Montefiore Einstein, the center offers a full array of diagnostic and treatment services under the direction of Medical Director Christopher Langston, MD, a fellowship-trained neurologist. With access to the latest advances in MS care, The Madlyn Borelli Multiple Sclerosis Center offers FLAIR (Fluid-Attenuated Inversion Recovery) imaging technology for improved diagnosis. In addition to diagnosis and treatment, the center provides rehabilitation services, including physical and occupational therapy as well as support and educational programs for patients and their families. The Madlyn Borelli Multiple Sclerosis Center is a designated Comprehensive Center for MS Care through the National Multiple Sclerosis Society's Partners in MS Care program. About the Burke Rehabilitation Center Burke Rehabilitation is a not-for-profit healthcare organization devoted solely to acute physical rehabilitation. Its main campus is located in White Plains, NY. Founded in 1915 through an endowment from philanthropist John Masterson Burke, it has been a member of the Montefiore Health System since 2016. Burke operates the only hospital in Westchester County dedicated solely to adult and adolescent rehabilitation medicine. Burke also offers therapeutic care in locations throughout Westchester County, the Hudson Valley and the Bronx for those who have experienced injuries, surgery, or chronic conditions, from the simple to the very complex. For additional information, please visit burke.org. About the PoNS Therapeutic Experience Program The PoNS Therapeutic Experience Program (“PoNSTEP”) is a Helius-sponsored, open label observational, interventional multi-center outcome research trial designed to assess adherence to on-label PoNS therapy for improvement in gait deficits for patients with multiple sclerosis (MS) in a real-world clinical setting. The study will rate subjects’ adherence to PoNS therapy, which combines the PoNS device with physical therapy, to better understand the relationship between adherence to the treatment regimen and therapeutic functional outcome. The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject’s adherence to PoNS therapy. The secondary endpoint is improvement of gait and balance deficit over time and clinical global impression of change. The study is currently undertaken at six site and aims to recruit up to seven or eight Centers of Excellence across the United States, with the potential of enrolling five to ten subjects per site. Enrollment began in the fourth quarter of 2022 and will continue throughout 2023. A total of fifty to sixty patients with MS are expected to take part in the program. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator (PoNS) is an innovative orally-applied, non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS is also authorized for sale in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com. Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding expected enrollment, patient participation and other details related to and outcomes of the PoNSTEP study and the ability of key opinion leaders in the management of MS to build their knowledge of PoNS® therapy and advise the broader medical community. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, disruptions in the banking system and financial markets, lingering impacts of the COVID-19 pandemic, the effect of macroeconomic conditions and the Company’s ability to access capital markets, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, availability of funds, manufacturing, labor shortage and supply chain risks, our ability to maintain and enforce our intellectual property rights, clinical trials and the clinical development process, the product development process, the regulatory submission review and approval process, our operating costs and use of cash, and our ability to achieve significant revenues, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations ContactLisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: email@example.com
NEW CANAAN, Conn., Aug. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mike Cotzas is acknowledged as a Pinnacle Life Healthcare Professional for his contributions to the field of Orthodontics.
Dr. Cotzas pursued higher education at New York University where he earned a Bachelor's degree in Biology. He continued at Columbia University where he earned his Doctor of Dental Surgery degree; completed a General Practice Residency at New York Hospital Medical Center of Queens; and was post-doctoral trained in orthodontics and dentofacial orthopedics at Montefiore Medical Center.
Mike Cotzas, DDS
Board-certified as an orthodontist, Dr. Cotzas works at Orthodontic Associates of New Canaan and notes that he helps each patient achieve the healthy, straighter smiles they deserve. He explained that the practice is limited to orthodontics for children and teens and the goal of Orthodontic Associates of New Canaan is to provide high-quality orthodontic treatments using the most innovative technology and materials for all patients and achieve the best outcome possible.
A devoted professional in his field, Dr. Cotzas attends conferences and completes continuing education courses to keep abreast of the latest innovations in orthodontics. He is a member of the American Board of Orthodontics (ABO), College of Diplomates of the American Board of Orthodontics; the American Dental Association; the American Association of Orthodontists (AAO); the Northeastern Society of Orthodontists; and the Connecticut State Dental Association. The ABO is the leader in orthodontic board certification and sets the standards of care for excellence in orthodontics and dentofacial orthopedics.
The doctor asserts that orthodontics is a specialty of dentistry that deals with the diagnosis and correction of mal-positioned teeth and jaws. Orthodontists, like Dr. Cotzas, are responsible for identifying problems with teeth, jaws, and fixing the bite for proper chewing. They utilize the most advanced procedures and equipment available to ensure that every patient achieves a healthy and beautiful smile.
Aside from his professional pursuits, Dr. Cotzas enjoys traveling, skiing, and being a foodie. He would like to dedicate this honor to his family and his parents, George and Dena Cotzas, and thank them for their love and support.
Contact: Katherine Green, 516-825-5634, [email protected]
SOURCE The Inner Circle